文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺放疗中直肠分离持续获益:III期试验最终结果

Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-12-23

这项单盲III期试验将222例接受图像引导调强放疗的前列腺癌患者按2:1随机分为水凝胶间隔组和对照组,中位随访3年。间隔组3级及以上直肠毒性、泌尿失禁及肠道生活质量下降均显著低于对照组,支持水凝胶间隔在前列腺放疗中的获益。

要点

  • 间隔组3年≥1级和≥2级直肠毒性发生率均显著低于对照组。
  • 间隔组≥1级泌尿失禁发生率更低,≥2级泌尿毒性无差异。
  • 间隔组肠道生活质量从6个月起持续更优,3年差异达最小重要差异阈值。

核心结论

  • 水凝胶间隔在图像引导调强放疗后减少直肠剂量、毒性和生活质量下降的获益随随访延长而维持或增加。

研究设计与样本

  • 单盲III期试验纳入222例前列腺癌患者,按2:1随机分为水凝胶间隔组或对照组。
  • 患者接受79.2 Gy分次1.8 Gy的前列腺放疗,伴或不伴精囊照射,中位随访3年。

主要发现

  • 3年≥1级直肠毒性间隔组9.2% vs 对照组2.0%(P=.028),≥2级5.7% vs 0%(P=.012)。
  • ≥1级泌尿失禁间隔组15% vs 对照组4%(P=.046),≥2级泌尿毒性7% vs 7%(P=0.7)。
  • 3年肠道生活质量间隔组优5.8分(P<.05),达到最小重要差异阈值。
  • 3年肠道生活质量最小重要差异下降比例间隔组41% vs 对照组14%(P=.002),泌尿30% vs 17%(P=.04)。
  • 3年肠道生活质量两倍最小重要差异下降比例间隔组21% vs 对照组5%(P=.02),泌尿23% vs 8%(P=.02)。

关键数值与推荐

  • 3年≥1级直肠毒性间隔组9.2% vs 对照组2.0%(P=.028)。
  • 3年≥2级直肠毒性间隔组5.7% vs 对照组0%(P=.012)。
  • 3年≥1级泌尿失禁间隔组15% vs 对照组4%(P=.046)。
  • 3年肠道生活质量最小重要差异下降间隔组41% vs 对照组14%(P=.002)。

临床怎么用

  • 在前列腺图像引导调强放疗中,使用水凝胶间隔可降低直肠毒性和肠道生活质量下降。
  • 水凝胶间隔可能减少泌尿失禁和泌尿生活质量下降,但需结合患者个体情况评估。

局限性

  • 单盲设计可能影响生活质量主观报告。
  • 中位随访3年,长期获益仍需更长时间随访确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: SpaceOAR, a Food and Drug Administration-approved hydrogel intended to create a rectal-prostate space, was evaluated in a single-blind phase III trial of image guided intensity modulated radiation therapy. A total of 222 men were randomized 2:1 to the spacer or control group and received 79.2 Gy in 1.8-Gy fractions to the prostate with or without the seminal vesicles. The present study reports the final results with a median follow-up period of 3 years. METHODS AND MATERIALS: Cumulative (Common Terminology Criteria for Adverse Events, version 4.0) toxicity was evaluated using the log-rank test. Quality of life (QOL) was examined using the Expanded Prostate Cancer Index Composite (EPIC), and the mean changes from baseline in the EPIC domains were tested using repeated measures models. The proportions of men with minimally important differences (MIDs) in each domain were tested using repeated measures logistic models with prespecified thresholds. RESULTS: The 3-year incidence of grade ≥1 (9.2% vs 2.0%; P=.028) and grade ≥2 (5.7% vs 0%; P=.012) rectal toxicity favored the spacer arm. Grade ≥1 urinary incontinence was also lower in the spacer arm (15% vs 4%; P=.046), with no difference in grade ≥2 urinary toxicity (7% vs 7%; P=0.7). From 6 months onward, bowel QOL consistently favored the spacer group (P=.002), with the difference at 3 years (5.8 points; P<.05) meeting the threshold for a MID. The control group had a 3.9-point greater decline in urinary QOL compared with the spacer group at 3 years (P<.05), but the difference did not meet the MID threshold. At 3 years, more men in the control group than in the spacer group had experienced a MID decline in bowel QOL (41% vs 14%; P=.002) and urinary QOL (30% vs 17%; P=.04). Furthermore, the control group were also more likely to have experienced large declines (twice the MID) in bowel QOL (21% vs 5%; P=.02) and urinary QOL (23% vs 8%; P=.02). CONCLUSIONS: The benefit of a hydrogel spacer in reducing the rectal dose, toxicity, and QOL declines after image guided intensity modulated radiation therapy for prostate cancer was maintained or increased with a longer follow-up period, providing stronger evidence for the benefit of hydrogel spacer use in prostate radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hamstra DA, Mariados N, Sylvester J, et al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys. 2016. PMID: 28209443. doi:10.1016/j.ijrobp.2016.12.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。